AntoXa Corporation
AntoXa Corporation is a Canadian biopharmaceutical company that develops plant-based medical countermeasures aimed at protecting military and civilian populations from biological and chemical threats, as well as emerging infectious diseases. Leveraging a proprietary plant molecular farming platform, AntoXa focuses on producing safe, effective, and affordable therapeutics such as antidotes for bioterrorism agents and treatments for pandemic threats. The company specializes in rapid, scalable manufacturing of recombinant proteins and antibodies for use in national stockpiles and public health emergency preparedness.
Industries
Nr. of Employees
small (1-50)
AntoXa Corporation
1920 Yonge Street, Suite 200, Toronto, Ontario, Canada, M4S 3E2
AntoXa Corporation is currently seeking investment
AntoXa Corporation is seeking a series-a investment in the range of 5m-20m
Products
Monoclonal antibody produced via plant expression system for use as an antidote to ricin poisoning; prevents ricin from penetrating cells.
Recombinant butyrylcholinesterase produced in plants; developed as a prophylactic countermeasure to organophosphate nerve agents like sarin and soman.
Recombinant human hemopexin produced in plants for treatment of respiratory damage from sickle cell disease and exposure to toxic halogens (e.g., chlorine gas).
Monoclonal antibody produced via plant expression system for use as an antidote to ricin poisoning; prevents ricin from penetrating cells.
Recombinant butyrylcholinesterase produced in plants; developed as a prophylactic countermeasure to organophosphate nerve agents like sarin and soman.
Recombinant human hemopexin produced in plants for treatment of respiratory damage from sickle cell disease and exposure to toxic halogens (e.g., chlorine gas).
Services
Drug development and manufacturing services for governmental and pharmaceutical clients using plant-based platforms.
Drug development and manufacturing services for governmental and pharmaceutical clients using plant-based platforms.
Expertise Areas
- Biodefense therapeutics development
- Plant molecular farming
- Recombinant antibody production
- Enzyme-based countermeasures
Key Technologies
- Plant molecular farming
- Recombinant antibody engineering
- Rapid plant-based protein expression platforms
- Mammalian-type glycosylation in plants
Key People
News & Updates
Canadian Intellectual Property Office allowance for a plant-based production process for anti-ricin antibody.
U.S. Patent Office granted a patent for a plant-based process to produce antibody for ricin exposure.
AntoXa and SwiftPharma presented plant-made anti-ricin antibody technology to the NATO Biological Defense Medical Expert Panel.
AntoXa awarded a Canadian government contract to advance plant-made butyrylcholinesterase as a countermeasure to nerve agents.
AntoXa announced a strategic agreement with SwiftPharma to accelerate and commercialize plant-made monoclonal antibody against ricin in EMEA regions.
Patent covering the process for manufacturing monoclonal antibodies against ricin using a plant-based system.
Canadian Intellectual Property Office allowance for a plant-based production process for anti-ricin antibody.
U.S. Patent Office granted a patent for a plant-based process to produce antibody for ricin exposure.
AntoXa and SwiftPharma presented plant-made anti-ricin antibody technology to the NATO Biological Defense Medical Expert Panel.
AntoXa awarded a Canadian government contract to advance plant-made butyrylcholinesterase as a countermeasure to nerve agents.
AntoXa announced a strategic agreement with SwiftPharma to accelerate and commercialize plant-made monoclonal antibody against ricin in EMEA regions.
Patent covering the process for manufacturing monoclonal antibodies against ricin using a plant-based system.